🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Dishman Carbogen Amcis Limited DCAL NSEPHARMA

Healthcare · Biotechnology · India
https://imdcal.com
Company Profile ↓
₹142.10
-41.47% 1Y
Mkt Cap₹2,227.89 Cr
P/E137.96
P/B0.35
52W High₹314.40
52W Low₹129.97
Book Value₹426.90
EPS (TTM)₹1.03

Company Overview

Dishman Carbogen Amcis Limited provides contract development and manufacturing organization (CDMO) services for the pharmaceutical and healthcare industries worldwide. It operates through Integrated CDMO Platform and Marketable Molecules segments. The company offers cholesterol and vitamin D analogs; soft gel capsules and formulations; intermediate and active pharmaceutical ingredients (APIs) which cover specific therapeutic areas, such as anesthetics, and contrast media agents for diagnostics, ophthalmic treatments, laxatives, and organophosphate antidotes; ammonium and phosphonium; quats, phosphoranes, and wittig reagents; generic intermediates; cholesterol and lanolin-related products; sterile injectables; specialty chemicals and disinfectants, as well as hand and body wash, sanitizers, and antiseptic formulations. It also provides encapsulation and formulation capabilities; phase transfer catalysts; drug product, finished, and HiPo formulations; generic and highpotent APIs; Health and personal care solutions; and drug linkers and payloads. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 142.3% per year over the last five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹2,931.90 Cr (+8.1% YoY); net profit ₹97.45 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -4.3%, earnings +2907.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.2%, profit CAGR 142.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.19%
1 Year:-4.30%

Compounded Profit Growth

5 Years:142.34%
1 Year:2,907.72%

Stock Price Performance

1 Year:-41.47%
6 Months:-15.92%
3 Months:-20.72%
1 Month:-16.66%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 7% of range
₹129.97 ₹314.40
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)29.03 · Oversold
Price Performance
1M-16.66%
3M-20.72%
6M-15.92%
1Y-41.47%
Valuation vs Sector

P/E of 137.96 is above the sector median of 36.43 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 142.3% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 138.0.
  • Trading 54.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
137.96
Industry PE
36.43
Forward P/E
11.37
PEG Ratio
-
Book Value
₹426.90
Price to Book
0.35
P/S
0.81
EV/EBITDA
8.67
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
8.19%
Profit 5Y
142.34%
Revenue (YoY)
-4.30%
Earnings (YoY)
2,907.72%

Profitability & Returns

ROCE
2.91%
ROE
1.46%
ROA
0.82%
Profit Margin
0.56%
Op Margin
-4.52%
Gross Margin
85.36%
EPS (Latest Qtr)
₹1.39
EPS (TTM)
₹1.03

Balance Sheet & Liquidity

Debt/Equity
0.46
Quick Ratio
0.79
Current Ratio
1.23
Debt
₹3,076.06 Cr
Total Assets
₹11,923.31 Cr
Current Assets
₹2,842.10 Cr
Working Capital
₹525.05 Cr

Ownership

Promoter Holding
69.30%
Chg in Prom Hold
9.98%
FII / Inst Holding
2.71%
Chg in FII Hold
0.04%

Financial Snapshot

Enterprise Value
₹2,227.89 Cr
Total Revenue (TTM)
₹2,901.49 Cr
EBITDA
₹504.01 Cr
Free Cash Flow
₹224.84 Cr
Operating Cash Flow
₹491.45 Cr
Shares Outstanding
₹15.68 Cr
Gross Margin
85.36%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 DCAL Dishman Carbogen Amcis Limited NSEPHARMA 142.10 137.96 ₹2,227.89 Cr 0.00% 2.91% 1.46% 8.19% 142.34%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 619.00 Cr723.00 Cr587.00 Cr651.00 Cr655.00 Cr524.00 Cr-682.34 Cr716.34 Cr708.05 Cr653.00 Cr719.80 Cr851.40 Cr
Cost of Revenue -------98.83 Cr145.91 Cr98.09 Cr-141.48 Cr134.91 Cr
Gross Profit -------583.51 Cr570.43 Cr609.96 Cr-578.32 Cr716.49 Cr
Operating Expenses 567.00 Cr602.00 Cr526.00 Cr610.00 Cr592.00 Cr495.00 Cr-515.35 Cr496.83 Cr550.63 Cr504.00 Cr549.63 Cr642.33 Cr
Operating Income -25.00 Cr52.00 Cr-14.00 Cr-39.00 Cr-22.00 Cr-42.00 Cr-68.16 Cr73.60 Cr59.33 Cr65.00 Cr28.69 Cr74.16 Cr
EBITDA 51.00 Cr122.00 Cr61.00 Cr41.00 Cr63.00 Cr29.00 Cr-147.80 Cr148.91 Cr162.78 Cr149.00 Cr119.77 Cr178.22 Cr
Interest Expense 24.00 Cr28.00 Cr27.00 Cr33.00 Cr31.00 Cr32.00 Cr-48.78 Cr42.12 Cr42.76 Cr42.00 Cr45.79 Cr43.30 Cr
Pretax Income -88.00 Cr29.00 Cr-36.00 Cr-66.00 Cr-49.00 Cr-78.00 Cr-27.05 Cr27.70 Cr38.67 Cr31.00 Cr-10.44 Cr46.13 Cr
Tax Provision 16.72 Cr12.18 Cr-4.68 Cr6.60 Cr-20.58 Cr-0-22.42 Cr-15.39 Cr15.26 Cr-35.34 Cr2.53 Cr24.39 Cr
Net Income -71.00 Cr17.00 Cr-41.00 Cr-60.00 Cr-70.00 Cr-78.00 Cr-4.63 Cr43.09 Cr23.41 Cr65.00 Cr-12.97 Cr21.74 Cr
Diluted EPS -4.511.08-2.61-3.80-4.46-4.95-0.302.751.494.16-0.831.39

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,031.00 Cr1,714.00 Cr1,695.00 Cr2,059.00 Cr2,044.00 Cr1,912.00 Cr-2,315.05 Cr2,543.62 Cr2,711.50 Cr2,931.90 Cr
Cost of Revenue -------534.21 Cr611.61 Cr501.65 Cr408.79 Cr
Gross Profit -------1,780.84 Cr1,932.01 Cr2,209.85 Cr2,523.11 Cr
Operating Expenses 830.00 Cr1,261.00 Cr1,249.00 Cr1,507.00 Cr1,540.00 Cr1,638.00 Cr-1,675.35 Cr1,973.33 Cr2,034.65 Cr2,296.17 Cr
Operating Income 132.00 Cr238.00 Cr234.00 Cr312.00 Cr220.00 Cr-34.00 Cr-105.49 Cr-41.32 Cr175.20 Cr226.94 Cr
EBITDA 201.00 Cr452.00 Cr445.00 Cr552.00 Cr503.00 Cr274.00 Cr-300.52 Cr302.01 Cr472.51 Cr617.77 Cr
Interest Expense 56.00 Cr49.00 Cr49.00 Cr57.00 Cr62.00 Cr48.00 Cr-74.39 Cr113.41 Cr159.46 Cr174.18 Cr
Pretax Income 91.00 Cr216.00 Cr231.00 Cr309.00 Cr197.00 Cr-65.00 Cr--54.59 Cr-122.26 Cr19.31 Cr104.90 Cr
Tax Provision 10.92 Cr71.28 Cr76.23 Cr98.88 Cr39.40 Cr-100.10 Cr--24.79 Cr31.19 Cr16.07 Cr7.45 Cr
Net Income 80.00 Cr145.00 Cr155.00 Cr210.00 Cr159.00 Cr-165.00 Cr--29.80 Cr-153.45 Cr3.24 Cr97.45 Cr
Diluted EPS --9.5813.0310.10-10.53--1.90-9.790.216.22

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 2,081.00 Cr6,574.00 Cr7,169.00 Cr7,321.00 Cr8,193.00 Cr8,356.00 Cr-9,453.50 Cr9,581.41 Cr9,999.15 Cr11,923.31 Cr
Current Assets -------1,918.36 Cr1,928.19 Cr2,200.42 Cr2,842.10 Cr
Cash & Equivalents -------131.79 Cr264.09 Cr341.07 Cr787.76 Cr
Inventory -------803.80 Cr882.89 Cr900.24 Cr1,019.12 Cr
Receivables -------589.91 Cr484.47 Cr665.14 Cr672.91 Cr
Total Liabilities -------3,643.83 Cr3,953.91 Cr4,167.63 Cr5,246.41 Cr
Current Liabilities -------1,798.39 Cr2,554.72 Cr1,924.79 Cr2,317.05 Cr
Long Term Debt -------1,043.22 Cr243.23 Cr1,147.02 Cr1,534.86 Cr
Total Debt 868.00 Cr950.00 Cr1,095.00 Cr1,042.00 Cr1,357.00 Cr1,589.00 Cr-2,208.85 Cr2,312.60 Cr2,388.95 Cr3,076.06 Cr
Total Equity 879.00 Cr4,814.00 Cr5,107.00 Cr5,379.00 Cr5,715.00 Cr5,698.00 Cr-5,809.67 Cr5,627.50 Cr5,831.52 Cr6,676.90 Cr
Shares Outstanding -------15.68 Cr15.68 Cr15.68 Cr15.68 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 203.00 Cr303.00 Cr226.00 Cr282.00 Cr585.00 Cr513.00 Cr-265.95 Cr379.43 Cr371.28 Cr491.45 Cr
Investing Cash Flow -231.00 Cr-107.00 Cr-297.00 Cr-169.00 Cr-442.00 Cr-380.00 Cr--494.08 Cr-229.52 Cr-192.21 Cr-245.34 Cr
Financing Cash Flow 25.00 Cr-137.00 Cr78.00 Cr-102.00 Cr-98.00 Cr-11.00 Cr-249.67 Cr-22.15 Cr-102.09 Cr200.58 Cr
Capital Expenditure -240.00 Cr-139.00 Cr-204.00 Cr-308.00 Cr-408.00 Cr-366.00 Cr--619.68 Cr-303.25 Cr-216.76 Cr-266.61 Cr
Free Cash Flow -37.00 Cr164.00 Cr22.00 Cr-26.00 Cr177.00 Cr147.00 Cr--353.73 Cr76.18 Cr154.52 Cr224.84 Cr
Net Change in Cash -3.00 Cr59.00 Cr7.00 Cr11.00 Cr46.00 Cr122.00 Cr-21.54 Cr127.76 Cr76.98 Cr446.69 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -------76.9%76.0%81.5%86.1%
Operating Margin % 12.8%13.9%13.8%15.2%10.8%-1.8%-4.6%-1.6%6.5%7.7%
Net Margin % 7.8%8.5%9.1%10.2%7.8%-8.6%--1.3%-6.0%0.1%3.3%
ROE % 9.1%3.0%3.0%3.9%2.8%-2.9%--0.5%-2.7%0.1%1.5%
ROCE % -------1.4%-0.6%2.2%2.4%

Shareholding Pattern

Insiders
69.30%
Institutions
2.71%
Public Float
8.82%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for DCAL

Google News Fri, 22 May 2026

With EPS Growth And More, Dishman Carbogen Amcis (NSE:DCAL) Makes An Interesting Case - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNZC1LVDJORWVDT2gwWWJCdjM3N3NXUXVJQ2lGdy1wMV8yUDVJRHBFZjNaRk5BbE1QRjRlbHNoSVVzaVhubkFFZEhDMjZCcW9zbEtKM3NwN0g3OG8wY2RuQlZOdVlKOUdHb1VfOEFXM3c1RE0yb1FyR1RRVFF1XzhscUM0V3o4Nlo5MDdPV2…

Google News hu, 07 May 2026

Why Is Dishman Carbogen Amcis Share Price Falling: Key Reasons and Investor Analysis 2026 - Univest

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE5RaUZKd3lGbGdYblRtV3l3OXhHUVFGajR4bGJ5ZmNKYnkwUVpRYVF4dDROZDlIVGJicXdQZlhIQ0RtZ1Z4YkVWcVhZVHU1MHZOQ25ZNF9vUm8tdEhxY2hlMzhuWElpbFRBNUstYmE4ZE82d0xnYXdwSnRhWWp3Q2c?oc=5" target="_bla…

Google News ue, 22 Sep 2026

Dishman Carbogen Amcis (DCAL.NS) Eases to ₹169.88 as Stock Consolidates Below ₹178 Resistance - ALMA Signal - https://www.siam.in/

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPRVF4R3pqQlkxTVhJTU8ydkJvdGNWOHBRb1liUXAwb3FoOFpVa3pTSUhxSTJ1VWktS1BGdFlHR0JoRk9LNWxuekVQbF81YUFvZ2g1RVZIQkxDdS1OczR2N1hvR0ZubkhJaFd4WnROTDNXMmJtc0tUd0twMmM0Mlc3UldFdGNHZkt3dUhBZX…

Google News ue, 04 Nov 2025

DCAL Share Price Today - Dishman Carbogen Amcis Stock Analysis - Equitypandit

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE5GN3FzaEY5MjItTFFZMV9mMGZHMGUtWTVVdU9valRoUFY5SkN4b3lRWVE5dkpLLWVpYWg1S3ZsY0RiVjJWckV3V05qdEtCd05CdTNLcWIxb1g?oc=5" target="_blank">DCAL Share Price Today - Dishman Carbogen Amcis …

Google News Sat, 06 Dec 2025

Why Investors Shouldn't Be Surprised By Dishman Carbogen Amcis Limited's (NSE:DCAL) 25% Share Price Plunge - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxQQVRVdjcwRUI0cTZpcnpnak5kaGdSaTBvczB5N0NOZ0xXaThKVzFSeFl1V0hKNUs0MW0tUXkzWTJUQWVYT0w2OFJQRjZPdzBXalZLODBsX2hkVndZdThEcUVoN1E4cEQyelJ6cFpnaGVGaC1uM3pFMlZrX3FlbWUwT3JTa3JMaFFkOEhla1…

Google News hu, 08 Oct 2026

Dishman Carbogen Amcis DCAL Reg 74(5) Certificate Q2 FY27 - Kalkine India

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQT2haNHpBNG5XU3BhSmp5eGpTV05PMXdrYWVNaERsbFhsUGFfaVpUNEtFbkNJUnVWMTAyLUhTekx2c2JzUEhmUUhlZk9wQjhzSVhyUy04THZDUzFNcnlpRzBSanRLd0Z0Q2h4ZWhpaVhNbkVTbUk0Q0JXcTJyTElGeUNPSHBqU0x4eUJQQT…

DCAL — Frequently Asked Questions

What is the current share price of Dishman Carbogen Amcis Limited (DCAL)?

As of 2026-10-23 04:58 IST, Dishman Carbogen Amcis Limited (DCAL) trades at ₹142.10 on NSE. Its 52-week range is ₹129.97 to ₹314.40.

What is the market capitalisation of DCAL?

Dishman Carbogen Amcis Limited (DCAL) has a market capitalisation of ₹2,227.89 Cr on NSE.

What is the P/E ratio of DCAL?

DCAL trades at a trailing price-to-earnings (P/E) ratio of 137.96. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 0.35.

What is the return on equity (ROE) of DCAL?

DCAL has a return on equity (ROE) of 1.46%. Its return on capital employed (ROCE) is 2.91%.

Is DCAL a good stock to buy?

This page provides a data-driven analysis of Dishman Carbogen Amcis Limited (DCAL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space